Zacks: NuCana PLC Sponsored ADR (NCNA) Given $24.00 Average Price Target by Brokerages

Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price objective of $24.00 for the company, according to Zacks. Zacks has also given NuCana PLC Sponsored ADR an industry rank of 115 out of 265 based on the ratings given to its competitors.

Several research firms recently issued reports on NCNA. Jefferies Group LLC began coverage on NuCana PLC Sponsored ADR in a research report on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Citigroup Inc. began coverage on NuCana PLC Sponsored ADR in a research report on Monday, October 23rd. They issued a “buy” rating and a $23.00 target price on the stock. William Blair began coverage on NuCana PLC Sponsored ADR in a research report on Monday, October 23rd. They set an “outperform” rating on the stock. Finally, Cowen and Company began coverage on NuCana PLC Sponsored ADR in a research report on Monday, October 23rd. They set an “outperform” rating on the stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/11/12/zacks-nucana-plc-sponsored-adr-ncna-given-24-00-average-price-target-by-brokerages.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. Sphera Funds Management LTD. acquired a new stake in NuCana PLC Sponsored ADR during the 3rd quarter worth about $919,000. Citadel Advisors LLC acquired a new stake in NuCana PLC Sponsored ADR during the 3rd quarter worth about $1,218,000. Finally, Baillie Gifford & Co. acquired a new stake in NuCana PLC Sponsored ADR during the 3rd quarter worth about $8,266,000. 3.51% of the stock is currently owned by institutional investors.

NuCana PLC Sponsored ADR (NCNA) traded down $0.04 during midday trading on Friday, hitting $11.00. The company had a trading volume of 45,900 shares, compared to its average volume of 72,058. NuCana PLC Sponsored ADR has a 52-week low of $9.64 and a 52-week high of $19.95.

NuCana PLC Sponsored ADR Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Get a free copy of the Zacks research report on NuCana PLC Sponsored ADR (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply